Key takeaways:

Use of alternative endpoints in phase 3 oncology trials continues to increase.

Just 28% of trials published in the past 20 years demonstrated OS improvement.

Perspective from Jorge Nieva, MD

CHICAGO — Positive interpretations of randomized phase 3 oncology trials often are based on improvements in unvalidated alternative endpoints, findings presented at ASCO Annual Meeting showed.

Improvements in OS or quality of life are uncommon and they are “exceedingly rare in combination,” according to researcher Alexander D. Sherry, MD , a radiation oncology resident at The University of Texas MD Anderson Cancer Center.

Data derived from Sherry AD, et al. Abstract 11005. Presented at: ASCO Annual Meeting; May 30-June 3, 2025; Chicago.

The findings highlight the need for re

See Full Page